5AM VENTURE MANAGEMENT LLC
Q3 2023 Form 13-F
SAN FRANCISCO, CALIFORNIA
CIK 0001799883
· CRD 160395
· SEC-registered investment adviser
$347.5M Reported Value Total
5AM VENTURES reports 11 total accounts under management (AUM). There are 11 discretionary accounts valued at $1,730,196,694, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
12 funds
· $947.0M gross asset value
Venture Capital Fund: $625.3M · Private Equity Fund: $271.8M · Hedge Fund: $49.9M
Source: Form ADV filed 2026-03-30
Reported value
$347.5M
Quarter over quarter
-14.6%
Holdings
26
Top-10 concentration
74.9%
Key People
Form ADV owners & control persons
Kush M Parmar
MEMBER, 5AM VENTURE MANAGEMENT, LLC
Andrew James Schwab
MEMBER, 5AM VENTURE MANAGEMENT LLC
Lauren Alison Daniel
CHIEF COMPLIANCE OFFICER, GENERAL COUNSEL
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2023 13F record
Q3 2023 13F filing summary
| Period of report | September 30, 2023 |
|---|---|
| Filed | November 14, 2023 |
| Form | 13F-HR |
| Reported value | $347.5M |
| Positions | 26 |
| Change in reported value | -13.4% |
| New positions | 2 |
| Exited positions | 0 |
| Position turnover | 7.7% |
| Top-10 concentration | 74.9% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
16 | $287.9M |
|
Q1 2026 13F
Filed May 15, 2026
|
20 | $360.2M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
21 | $318.1M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
25 | $273.0M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
29 | $260.1M |
|
Q1 2025 13F
Filed May 15, 2025
|
31 | $264.4M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
31 | $419.1M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
28 | $484.0M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
28 | $447.1M |
|
Q1 2024 13F
Filed May 15, 2024
|
26 | $446.6M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
25 | $377.0M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
26 | $347.5M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
24 | $401.4M |
|
Q1 2023 13F
Filed May 15, 2023
|
24 | $391.0M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
21 | $372.1M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
21 | $522.0M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
21 | $404.2M |
|
Q1 2022 13F
Filed May 16, 2022
|
19 | $457.8M |
|
Q4 2021 13F
Filed Feb 3, 2022
|
17 | $532.8M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
16 | $492.5M |
7 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q3 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ELVN ENLIVEN THERAPEUTICS INC | $70.5M | 20.29% |
| 2 | TRDA ENTRADA THERAPEUTICS INC | $69.7M | 20.04% |
| 3 | IRON DISC MEDICINE INC | $20.6M | 5.93% |
| 4 | DNTH DIANTHUS THERAPEUTICS INC | $20.1M | 5.79% |
| 5 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | $17.9M | 5.14% |
| 6 | CRNX CRINETICS PHARMACEUTICALS IN | $13.7M | 3.96% |
| 7 | VOR VOR BIOPHARMA INC | $13.5M | 3.88% |
| 8 | PHVS PHARVARIS N V | $12.3M | 3.53% |
| 9 | RLYB RALLYBIO CORP | $12.2M | 3.52% |
| 10 | ZNTL ZENTALIS PHARMACEUTICALS INC | $9.8M | 2.83% |
| 11 | SCPH SCPHARMACEUTICALS INC | $8.5M | 2.46% |
| 12 | CLDX CELLDEX THERAPEUTICS INC NEW | $8.5M | 2.46% |
| 13 | MRTX MIRATI THERAPEUTICS INC | $8.4M | 2.41% |
| 14 | COGT COGENT BIOSCIENCES INC | $7.7M | 2.22% |
| 15 | VKTX VIKING THERAPEUTICS INC | $6.5M | 1.86% |
| 16 | ANAB ANAPTYSBIO INC | $6.4M | 1.85% |
| 17 | VRDN VIRIDIAN THERAPEUTICS INC | $6.3M | 1.81% |
| 18 | ARVN ARVINAS INC | $6.3M | 1.81% |
| 19 | TYRA TYRA BIOSCIENCES INC | $5.7M | 1.63% |
| 20 | SPRB SPRUCE BIOSCIENCES INC | $5.3M | 1.54% |
Values as reported on the Q3 2023 Form 13F. Every position is in the holdings table below.